USFDA completes inspection of Jubilant Pharmova's API manufacturing facility

15 Dec 2022 , 09:16 AM

Jubilant Pharmova Limited announced that inspection of the Active Pharmaceutical Ingredients (API) manufacturing facility at Nanjangud on December 13, 2022 by the United States Food and Drug Administration (USFDA) has concluded.

Accordingly, the USFDA has issued eight observations pursuant to the completion of the inspection. The company will submit an action plan on the observations and will engage with USFDA for next steps.

At around 9:16 AM, Jubilant Pharmova was trading at Rs410 per share higher by 1.30% on the BSE.

For feedback and suggestions, write to us at [e-mail]